Banyan Biomarkers Announces U.S. Patent For Neural Proteins As Biomarkers For Traumatic Brain Injury

�Banyan Biomarkers, Inc. proclaimed that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,396,654 B2 "Neural Proteins as Biomarkers for Traumatic Brain Injury," licensed entirely by Banyan Biomarkers from the University of Florida. Specifically, the patent covers the spotting of certain neuronal protein markers set up in the blood of patients suffering from neuronal injury and / or neuronal hurt. The patent also covers certain sensitive and rapid methods and test kits that can buoy be victimized as tools for the diagnosis of neural injuries and/or neuronic disorders such as brain injury, neural damage due to do drugs or alcohol addiction and diseases associated with the brain and central spooky system.


Banyan Biomarkers too holds the exclusive permit from the University of Florida for U.S. Patent No. 7,291,710 "Detection of spectrin and spectrin proteolytic cleavage products in assessing nerve cellular phone damage."


Gary Ascani, Chief Executive Officer of Banyan Biomarkers, Inc., commented, "Banyan continues to effectively build its intellectual property portfolio and broaden our applications for biomarkers as critical tools for assisting physicians in diagnosis and managing patients with traumatic brain injuries and other acute central nervous system injuries such as stroke."


Approximately 1.9 million traumatic brain injuries are sustained annually. In a comparison provided by the Brain Injury Association of America, more traumatic brain injuries occur annually than the combined incidences of multiple sclerosis, spinal anaesthesia cord injuries, HIV/AIDS and breast cancer.

Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic mastermind injury. The company is focused on developing a simple point-of-care blood test that volition be used by physicians to discover the presence and austereness of head trauma and facilitate the diagnosis and management of head injured patients. Banyan Biomarkers also uses the company's proprietary biomarkers to provide testing services for the pharmaceutic industry in the rating of do drugs candidates for pre-clinical and clinical studies.

Banyan Biomarkers


More info

• Linseed food to keep cancer at bay
• Blood calcium levels may be tipoff for deadly prostate cancer
• Antihypertensive Treatment On Cognitive Functions In Alzheimer’s Disease
• Calif. Court Ruling On Physician Discrimination Based On Sexual Orientation Allows Equal Treatment, Editorial Says
• Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins